Many people find they feel satisfied after eating much smaller meals and are less likely to think about food throughout the day
Primary patency remained high at 93.3% at 1 month and 92.9% at 36 months, outperforming controls (89% at 1 month and 75% at 36 months)
External resources NEJM Phase 2 Trial: Triple Hormone Receptor Agonist Retatrutide for Obesity PMC Review: Retatrutide - A Game Changer in Obesity Pharmacotherapy ClinicalTrials.gov: Retatrutide TRIUMPH Clinical Trial Registry Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol builders, dosing calculators, and a community of thousands who have navigated these exact questions
Taken together, these studies highlight GLP1-Ss potential as a valuable research tool for exploring the neuroendocrine regulation of appetite and long-term body weight control
This material is intended exclusively for research and analytical purposes and is not approved for human or animal consumption
Specific protocols depend on experimental design
